FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia

To the editor: Acute promyelocytic leukemia (APL) is characterized by the promyelocytic leukemia-retinoic acid receptor α ( PML-RARA ) fusion. In rare instances, RARA is fused to other partners, which dictate sensitivity to targeted therapies. Chen et al previously reported in Blood a novel TBLR1